Mary Newman - Boundless Bio, Senior Vice President - Regulatory Affairs
President
Ms. Mary Newman is Senior Vice President Regulatory Affairs of the AUDENTES THERAPEUTICS, INC. Prior to joining Audentes, Ms. Newman served as the Senior Vice President, Regulatory Affairs and Quality Assurance at SARcode Bioscience Inc., which was acquired by Shire Ltd. She previously held various management positions, with increasing responsibility in Regulatory Affairs at BioMarin Pharmaceutical, Inc., Berlex Inc., and Sequus Pharmaceuticals, Inc. . While at BioMarin, Ms. Newman oversaw the development and approval of Kuvan for the treatment of phenylketonuria, Naglazyme for mucopolysaccharidosis VI, and supported the final approval of Aldurazyme for MPS I. She has also held various research and development leadership roles in oncology, neurology, and antifungal therapeutic areas since 2014.
Age | 58 |
Tenure | 10 years |
Phone | 415 818-1001 |
Web | www.audentestx.com |
Mary Newman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mary Newman against Boundless Bio, stock is an integral part of due diligence when investing in Boundless Bio,. Mary Newman insider activity provides valuable insight into whether Boundless Bio, is net buyers or sellers over its current business cycle. Note, Boundless Bio, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Boundless Bio,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mary Newman over six months ago Sale by Mary Newman of 2000 shares of IES Holdings |
Boundless Bio, Management Efficiency
The company has return on total asset (ROA) of (28.42) % which means that it has lost $28.42 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (50.57) %, meaning that it created substantial loss on money invested by shareholders. Boundless Bio,'s management efficiency ratios could be used to measure how well Boundless Bio, manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 29.89 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Boundless Bio, Common has a current ratio of 12.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Boundless Bio, until it has trouble settling it off, either with new capital or with free cash flow. So, Boundless Bio,'s shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Boundless Bio, Common sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Boundless to invest in growth at high rates of return. When we think about Boundless Bio,'s use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Scott Bowman | Dave Busters Entertainment | 51 | |
Scott Felenstein | National CineMedia | 55 | |
Michael Plunkett | Dave Busters Entertainment | 66 | |
Scott Palmer | Sapiens International | N/A | |
Sarah Hilty | National CineMedia | 47 | |
Liana Gelikas | Sapiens International | N/A | |
Lawrence Snapp | National CineMedia | 78 | |
Joe Deprospero | Dave Busters Entertainment | 43 | |
Clifford Marks | National CineMedia | 56 | |
Hui Liang | NetSol Technologies | N/A | |
Margo Manning | Dave Busters Entertainment | 52 | |
Craig Abrahams | Playtika Holding Corp | 47 | |
James Plunkett | Dave Busters Entertainment | 65 | |
Steve Rooney | Sapiens International | N/A | |
Angelia Pelham | Dave Busters Entertainment | 48 | |
Sean Gleason | Dave Busters Entertainment | 52 |
Management Performance
Return On Equity | -50.57 | |||
Return On Asset | -28.42 |
Boundless Bio, Common Leadership Team
Elected by the shareholders, the Boundless Bio,'s board of directors comprises two types of representatives: Boundless Bio, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boundless. The board's role is to monitor Boundless Bio,'s management team and ensure that shareholders' interests are well served. Boundless Bio,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boundless Bio,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Soloway, CFO, Senior Vice President | ||
Fulvio Mavilio, Senior Vice President - Translational Science | ||
Andrew Chang, Director, Investor Relations | ||
Eric Mosbrooker, Senior Vice President and Chief Commercial Officer | ||
Jonathan Silverstein, Chairman of the Board | ||
Thomas Woiwode, Independent Director | ||
Mark Meltz, Senior Vice President General Counsel | ||
Jennifer Jarrett, Director | ||
Stephen Squinto, Independent Director | ||
Edward Conner, Senior Vice President and Chief Medical Officer | ||
Matthew Patterson, President CEO, Co-Founder, Director | ||
Tom Woiwode, Board Director | ||
David Nagler, Senior Vice President - Human Resources and Corporate Affairs | ||
Louis Lange, Independent Director | ||
Mary Newman, Senior Vice President - Regulatory Affairs | ||
Scott Morrison, Independent Director | ||
John Gray, Senior Vice President - Research and Development | ||
Thomas Schuetz, Board Director | ||
Suyash Prasad, Senior Vice President Chief Medical Officer | ||
Mark Goldberg, Director | ||
Sarah Spencer, Vice President Corporate Communications | ||
Julie Smith, Director | ||
Natalie Holles, COO, Senior Vice President | ||
Kush Parmar, Board Director |
Boundless Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boundless Bio, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -50.57 | |||
Return On Asset | -28.42 | |||
Current Valuation | 2.42 B | |||
Shares Outstanding | 45.86 M | |||
Shares Owned By Insiders | 7.30 % | |||
Shares Owned By Institutions | 92.70 % | |||
Number Of Shares Shorted | 1.7 M | |||
Price To Earning | (7.22) X | |||
Price To Book | 7.15 X | |||
EBITDA | (169.76 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Boundless Bio, in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Boundless Bio,'s short interest history, or implied volatility extrapolated from Boundless Bio, options trading.
Pair Trading with Boundless Bio,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Boundless Bio, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Boundless Bio, will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to GameStop Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GameStop Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GameStop Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GameStop Corp to buy it.
The correlation of GameStop Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GameStop Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GameStop Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GameStop Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Boundless Stock
If you are still planning to invest in Boundless Bio, Common check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Boundless Bio,'s history and understand the potential risks before investing.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |